Class / Patent application number | Description | Number of patent applications / Date published |
514259400 | The second ring of the bicyclo ring system is six-membered, consisting of five ring carbons and the shared ring nitrogen (e.g., pyrido[1,2-a]pyrimidine, etc.) | 64 |
20080249112 | Mitotic Kinesin Inhibitors - The present invention relates to compounds that are useful for treating cellular proliferative diseases, for treating disorders mediated, at least in part, by KSP, and for inhibiting KSP. The invention also related to pharmaceutical compositions comprising such compounds, methods of treating cancer by the administration of such compositions, and processes for the preparation of the compounds. Compounds of the invention have the following formula: formula (I). | 10-09-2008 |
20100160346 | NEUROLOGICALLY ACTIVE COMPOUNDS - The present invention relates to neurologically-active compounds, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease. | 06-24-2010 |
20100168136 | ALKYLSULFONE DERIVATIVES - A compound having activity to inhibit production and/or secretion of β-amyloid protein, and is useful for prevention and/or treatment of various diseases associated with abnormal production and/or secretion of β-amyloid protein, the compound represented by the general formula (I): | 07-01-2010 |
20100267748 | HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses 1H-pyrido[1,2-a]pyrimidin-4(9aH)-one derivatives or 1H-pyrimido[1,2-a]pyrimidin-4(9aH)-one derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 10-21-2010 |
20110160227 | Prolyl Hydroxylase Inhibitors - The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I) | 06-30-2011 |
20130184294 | Pyrimidones for Treatment of Potassium Channel Related Diseases - The present invention relates to compounds of Formula I as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient. | 07-18-2013 |
20140288095 | PYRIDOPYRIMIDINONE INHIBITORS OF VIRUSES - Provided herein are novel small molecule pyridomyrimidone viral inhibitor agents of Formula (I), such as 4-acetyl-2,3,7,8-tetrahydro-3-phenylpyrido[1,2-f]pyrimidin-1-one, and methods of using pharmaceutical or therapeutic compositions comprising such viral inhibitor agents of Formula (I) in inhibiting and treating viral infections including orthopox and retroviral infections. Methods of synthesizing such agents are also provided herein. | 09-25-2014 |
514259410 | Additional hetero ring is attached directly or indirectly to the bicyclo ring system by nonionic bonding | 57 |
20080269257 | Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives - The invention relates to use of a pyrimidone derivative represented by formula (I) or a salt thereof as therapeutic agents: | 10-30-2008 |
20080287464 | Depot Formulations - Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity. | 11-20-2008 |
20090036470 | PALIPERIDONE DERIVATIVES - A compound of formula (1) is useful as a pharmaceutical and as an intermediate in making paliperidone. | 02-05-2009 |
20090048272 | PREPARATION OF PALIPERIDONE - Processes for preparing paliperidone. | 02-19-2009 |
20090076035 | DEUTERIUM-ENRICHED PALIPERIDONE - The present application describes deuterium-enriched peliperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090076036 | DEUTERIUM-ENRICHED RISPERIDONE - The present application describes deuterium-enriched risperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090163519 | DOSING REGIMEN ASSOCIATED WITH LONG ACTING INJECTABLE PALIPERIDONE ESTERS - The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations. | 06-25-2009 |
20090209558 | Polymer formulations for delivery of bioactive materials - Delivery of drugs in association with PLGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units. | 08-20-2009 |
20090247553 | Highly Pure Paliperidone or a Pharmaceutically Acceptable Salt Thereof Substantially Free of Keto Impurity - Provided herein is a highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4,9-dione, a process for the preparation thereof, and pharmaceutical compositions comprising highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity. | 10-01-2009 |
20100029691 | FAST ONSET ORODISPERSABLE TABLETS - The present invention provides orodispersable tablets and methods of using the same. The tablets and methods are useful, for example, for reducing first pass metabolism of orally administered active agents, enhancing bioavailability of active agents, and/or reducing the time it takes for an active agent to achieve maximal effect in a subject. The tablets, when taken orally, disintegrate or dissolve rapidly such that active agent included in the tablets is absorbed in the buccal cavity. The invention further provides methods of manufacturing any of the tablets disclosed herein and containers that include any of the tablets disclosed herein. | 02-04-2010 |
20100063070 | COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS - There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a statin, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atheresclerosis and related conditions. | 03-11-2010 |
20100093762 | METHODS FOR TREATING OR PREVENTING SYMPTOMS OF HORMONAL VARIATIONS - A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT | 04-15-2010 |
20100113482 | Novel Compounds for Treating Mental Disorders, and Preparation and Uses Thereof - The present invention relates to a compound of formula (I), an optical isomer or a pharmaceutically acceptable salt thereof, its preparation and uses, wherein R is defined as herein. Such compounds can be presented as an optical isomer or a racemic mixture. The compounds can be metabolized in vivo to form a pharmacologically active substance as antagonist of neurotransmitters, and can be used for the treatment of the related mental disorders such as schizophrenia. | 05-06-2010 |
20100113483 | COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS - The present invention provides novel compositions comprising a combination of a 5-HT | 05-06-2010 |
20100160347 | PYRIDO[1,2-a]PYRIMIDIN-4-ONE INHIBITORS OF MAST CELL DEGRANULATION - The present invention relates to new pyrido[1,2-a]pyrimidin-4-one inhibitors of mast cell degranulation, pharmaceutical compositions thereof, and methods of use thereof. | 06-24-2010 |
20100168137 | COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS - There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) ramatroban, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atherosclerosis and related conditions. | 07-01-2010 |
20100184783 | COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY ATHEROSCLEROSIS COMPRISING A MAST CELL INHIBITOR AND A PPAR GAMMA AGONIST - There is provided combination products comprising (a) a mast cell inhibitor, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a PPAR | 07-22-2010 |
20100292254 | Fused Pyrimidine Derivatives as Trpv3 Modulators - The present invention related to fused pyrimidine derivatives, which are useful as Transient Receptor Potential Vanilloid 3 (TRPV3) receptors, methods of treating deseases, disorders, conditions modulated by TRPV3. The present invention having the formula (I) and its pharmaceutically acceptable salts thereof, and its processes thereof, wherein all variables are as described herein. | 11-18-2010 |
20110053960 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS - The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels. | 03-03-2011 |
20110071167 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) - The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions. | 03-24-2011 |
20110105536 | DOSING REGIMEN ASSOCIATED WITH LONG-ACTING INJECTABLE PALIPERIDONE ESTERS - The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides a method for treating psychiatric patients in need of a switching treatment to paliperidone palmitate in a sustained release formulation. | 05-05-2011 |
20110112116 | COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS - Methods are provided for partial aortic obstruction for cerebral perfusion augmentation in patients suffering from global or focal cerebral ischemia. Alternatively, the methods can be used to partially obstruct aortic blood flow to condition the spinal cord to secrete neuroprotective agents prior to abdominal aortic aneurysm repair. Partial obstruction of a vessel can be accomplished by a device comprising an elongate catheter and a distally mounted expandable member. The expandable member may comprise one or two balloons. Other medical devices, such as an angioplasty, stent, or atherectomy catheter, can be inserted distal the expandable member to provide therapeutic intervention. | 05-12-2011 |
20110144132 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 06-16-2011 |
20110144133 | SUBSTITUTED PYRIMIDONE DERIVATIVES - Pyrimidone derivatives of formula (I) | 06-16-2011 |
20110172251 | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists - The present invention relates to methods of treating the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability—hypersensitivity—hyperaesthesia—dissociative phenomena— . . . ) using compounds and compositions of compounds having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds. | 07-14-2011 |
20110195981 | METHODS AND DOSAGE FORMS FOR REDUCING SIDE EFFECTS OF BENZISOZAZOLE DERIVATIVES - Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient. | 08-11-2011 |
20110212976 | DEUTERIUM-ENRICHED RISPERIDONE - The present application describes deuterium-enriched risperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 09-01-2011 |
20110257200 | Treatment of Acne and Other Diseases - The invention relates to compounds for the treatment of dermatological diseases where inflammation, matrix metalloproteinases (MMPs) and peroxisome proliferator-activated receptors (PPARs) play a role in mediating the disease, such as the treatment of acne with Pemirolast or a closely related compound thereof. | 10-20-2011 |
20110269777 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY - The present invention relates to combination therapies and methods for treating, preventing and/or delaying the onset and/or development of schizophrenia, wherein the combination therapies comprise a hydrogenated pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof, such as dimebon, and an antipsychotic. | 11-03-2011 |
20120083502 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 04-05-2012 |
20120196877 | COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS - The present invention provides novel compositions comprising a combination of a 5-HT | 08-02-2012 |
20120208828 | Azole Derivatives as WTN Pathway Inhibitors - The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas. | 08-16-2012 |
20120225893 | COMBINATION OF AN ANTIPSYCHOTIC AND AN ANTI-INFLAMMATORY AGENT - The present invention relates to a pharmaceutical composition comprising an antipsychotic in combination with an anti-inflammatory agent, and to the use thereof in the treatment of psychotic disorder, and in particular, of schizophrenia. | 09-06-2012 |
20120277253 | SUBCUTANEOUS PALIPERIDONE COMPOSITION - The present invention relates to pharmaceutical composition for subcutaneous injection comprising a paliperidone compound wherein the composition releases the paliperidone with an immediate onset of action and continuously for at least 3 weeks, and wherein the composition has a pharmacokinetic profile in vivo with substantially no burst release of the paliperidone. The compositions are useful as medicaments for the treatment of psychotic disorders and diseases. | 11-01-2012 |
20120283275 | METHODS AND DOSAGE FORMS FOR REDUCING SIDE EFFECTS OF BENZISOZAZOLE DERIVATIVES - Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient. | 11-08-2012 |
20120289521 | Treatment of Acne and Other Diseases - The invention relates to compounds for the treatment of dermatological diseases where inflammation, matrix metalloproteinases (MMPs) and peroxisome proliferator-activated receptors (PPARs) play a role in mediating the disease, such as the treatment of acne with Pemirolast or a closely related compound thereof. | 11-15-2012 |
20120329813 | Pemirolast for the Treatment of Systemic Low Grade Inflammation - According to the invention there is provided pemirolast, or a pharmaceutically acceptable salt thereof, for use in the treatment of systemic low-grade inflammation. | 12-27-2012 |
20130012524 | STABILIZED PROLONGED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING ATYPICAL ANTIPSYCHOTIC - The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and/or water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions. | 01-10-2013 |
20130018059 | DIMETHYL SULFOXIDE (DMSO) FORMULATIONS FOR TREATING AUTISM - Embodiments of the invention relate generally to formulations comprising dimethyl sulfoxide (DMSO) to treat behavioral disorders, communication delays, and developmental delays. Several formulations disclosed herein are useful for treating broad autism phenotype disorders, including autism spectrum disorders (e.g., autism). | 01-17-2013 |
20130053405 | CARRIER LINKED PALIPERIDONE PRODRUGS - The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent Paliperidone carrier conjugate of formula (I) | 02-28-2013 |
20130059865 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES - The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Pharmaceutical compositions comprising a compound of formula (I) are also provided. | 03-07-2013 |
20130143901 | COMBINATION OF PIMAVANSERIN AND RISPERIDONE FOR THE TREATMENT OF PSYCHOSIS - Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic. | 06-06-2013 |
20130331402 | DOSING REGIMEN ASSOCIATED WITH LONG-ACTING INJECTABLE PALIPERIDONE ESTERS - The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides a method for treating psychiatric patients in need of a switching treatment to paliperidone palmitate in a sustained release formulation. | 12-12-2013 |
20140045864 | ACID ADDITION SALTS OF RISPERIDONE AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to a novel acid addition salt of risperidone, wherein acid counterion is selected from the group consisting of pamoic acid, caproic acid, cypionic acid, decanoic acid, camphor sulfonic acid, enanthic acid, palmitic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic acid, lauric acid, levulinic acid and valeric acid, a process for the preparation and pharmaceutical composition comprising the same. Further, the invention relates to the use of said pharmaceutical composition comprising the acid addition salt of risperidone in the treatment of patient suffering from psychotic disorders. | 02-13-2014 |
20140088120 | Modulators of Androgen Synthesis - The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds. | 03-27-2014 |
20140128412 | COMBINATION OF AN ANTIPSYCHOTIC AND AN ANTI-INFLAMMATORY AGENT - The present invention relates to a pharmaceutical composition comprising an antipsychotic in combination with an anti-inflammatory agent, and to the use thereof in the treatment of psychotic disorder, and in particular, of schizophrenia. | 05-08-2014 |
20140200228 | PROCESS FOR THE PREPARATION OF PALIPERIDONE - The present invention provides a process for the preparation of paliperidone or a pharmaceutically acceptable salt thereof, wherein the process comprises condensing a compound of formula (II) | 07-17-2014 |
20140296257 | High-Loading Water-Soluable Carrier-Linked Prodrugs - The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independently a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use as medicament or diagnostic, and methods of treatment. | 10-02-2014 |
20140303189 | PATCH - The invention provides a patch containing a support and, formed thereon, an adhesive layer retaining a drug. The adhesive layer contains a thermoplastic elastomer, a liquid component in an amount exceeding 300 parts by weight relative to 100 parts by weight of the elastomer, and risperidone or a salt thereof, and optionally a tackifier of not more than 10 wt %. | 10-09-2014 |
20140329839 | New Crystalline Form of Pemirolast - There is provided a hemihydrate form of the sodium salt of pemirolast. | 11-06-2014 |
20140343080 | DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF - The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention. | 11-20-2014 |
20140378476 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS - The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels. | 12-25-2014 |
20150099767 | SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUNDS - The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof. | 04-09-2015 |
20160030386 | PREVENTION OF ROSACEA INFLAMMATION - The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and/or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea. | 02-04-2016 |
20160038493 | NOVEL CRYSTALLINE FORMS - The present invention relates to novel crystalline polymorphic forms of 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. The present invention also includes the methods of making crystalline polymorphic forms thereof and the use thereof for preparing a pharmaceutical composition. | 02-11-2016 |
20160143851 | PREPARATION OF POLYLACTIDE-POLYGLYCOLIDE MICROPARTICLES HAVING A SIGMOIDAL RELEASE PROFILE - The present invention relates to preparation of biodegradable microparticles formed from polylactide-polyglycolide copolymers (PLGA) polymer and how to achieve sigmoidal release of active pharmaceutical compound from the microparticles. In particular, the present invention relates to emulsification of an inner/oil phase to an outer/water phase followed by quenching and a single drying step for the preparation of microparticles having a preferred release profile of preferably basic/nucleophilic compounds such as risperidone. Alternatively the present invention is also suitable for hydrophobic compounds that have poor water-solubility and a high drug loading of >20% w/w is required. The release profile can be controlled by adjusting the degree of saturation of the outer/water phase with the organic solvent used in the inner/oil phase, the polymer concentration of the inner/oil phase and the temperature at the quenching step. In particular, an initial lag phase and a substantially sigmoidal release profile are achieved by using an outer aqueous phase over saturated with the solvent used in the inner phase at emulsification step, in combination with a low temperature during quenching. | 05-26-2016 |
20160175311 | USE OF PEMIROLAST IN THE TREATMENT OF ACUTE ASTHMA | 06-23-2016 |